OpenScience.ink

3 weeks ago • Health affairs scholar

Differences by social and demographic factors in prescribing semaglutide and tirzepatide for obesity treatmentSociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment.

Article

3 weeks ago • Disease-a-month : DM

Current use of GLP-1 drugs for treating substance abuse: A systematic reviewStatus Of GLP-1 drugs and their application in treating substance use disorders: A systematic review.

📖 Top 50% JournalArticle

3 weeks ago • Frontiers in pharmacology

Tirzepatide compared to other diabetes medicines for preventing foot problems in type 2 diabetesTirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes.

📖 Top 20% JournalArticle

3 weeks ago • Obesity science & practice

What Patients Know About Weight-Loss Drugs and How They Might Affect Their Households in a City Health SystemPatient Knowledge of GLP-1 Receptor Agonists for Obesity and Exploration of Potential Household-Level Effects in an Urban Health System.

📖 Top 30% JournalArticle

3 weeks ago • The American journal of cardiology

How Social and Economic Disadvantages Relate to Heart Failure Treatment Results with GLP-1 MedicinesAssociation between Socioeconomic Deprivation and Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure.

📖 Top 20% JournalArticle

3 weeks ago • Medicine

Short-term benefits and side effects of semaglutide plus dapagliflozin in type 2 diabetes patients with kidney diseaseShort-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease.

📖 Top 50% JournalObservational Study

3 weeks ago • Journal of the American Society of Nephrology : JASN

Estimating Who Qualifies for Combined Heart and Kidney Treatment and How Many Deaths Could Be PreventedA Microsimulation of Eligibility for Cardiorenal Combination Treatment and Potential Deaths Averted.

Article

3 weeks ago • Advances in medical sciences

Tirzepatide use, sticking to treatment, and dose increases in Polish patients facing high personal costsTirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.

📖 Top 30% JournalArticle

3 weeks ago • ACS omega

A Peptide Blocking PTPN1/N2 Proteins Improves Long-Lasting Blood Sugar Control and Weight Loss in MiceThe PTPN1/N2 Peptide Inhibitor Achieves Potent, Long-Acting Glycemic Control and Weight-Loss Dual Efficacy in Mice.

📖 Top 30% JournalArticle

3 weeks ago • Journal of internal medicine

Serious side effects of GLP-1 receptor drugs: what is known, uncertain, and important for treatmentGLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications.

🥉 Top 5% JournalArticle

3 weeks ago • Journal of the American Pharmacists Association : JAPhA

Guidelines for using incretin-based treatments to manage weightA stewardship framework for incretin-based therapies in weight management.

📖 Top 30% JournalArticle

3 weeks ago • Clinical obesity

Weight loss after stomach surgery compared to tirzepatide treatment in a minority group with severe obesityWeight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.

📖 Top 30% JournalComparative Study

3 weeks ago • JAMA

Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online May Not Be Safe or EffectiveUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.

Article

3 weeks ago • Clinical kidney journal

Communication between the gut and kidneys is reduced in people with type 2 diabetesGut-kidney signaling is impaired in individuals with type 2 diabetes.

🎖️ Top 10% JournalArticle

3 weeks ago • Surgical endoscopy

Starting semaglutide six months after sleeve gastrectomy and its effects on long-term weight loss and metabolismThe impact of semaglutide initiated six months after laparoscopic sleeve gastrectomy on long-term weight loss and metabolic outcomes: single-center preliminary study.

📖 Top 20% JournalArticle

3 weeks ago • Translational and clinical pharmacology

How movement affects drug interactions with GLP-1 receptor agonists: clear evidence and a way to measure themMotility-mediated drug interactions with GLP-1 receptor agonists: labeled evidence and a framework for quantitative assessment.

📖 Top 50% JournalArticle

3 weeks ago • American journal of obstetrics and gynecology

How Birth Control and Diabetes Drugs Affect Metabolism and Reproductive HealthContraceptive use and GLP-1 receptor agonists: an intersection of metabolic and reproductive health.

🥉 Top 5% JournalArticle

3 weeks ago • Obesity (Silver Spring, Md.)

Cost-Effectiveness and Fairness of Using Semaglutide to Treat ObesityThe Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment.

🎖️ Top 10% JournalArticle

3 weeks ago • Research square

Low-Dose GLP-1 Therapy May Change Heart Blood Vessels and Fat Molecules in Heart Failure with Metabolic ProblemsDirect Coronary Vascular and Lipidomic Remodeling by Low-Dose GLP-1 Agonist Therapy in Cardiometabolic HFpEF.

Preprint

3 weeks ago • Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery

Incretin’s role in type 2 diabetes remission after gastric bypass surgeryIncretin influence on type 2 diabetes mellitus remission after Roux-en-Y gastric bypass.

📖 Top 50% JournalArticle

3 weeks ago • Climacteric : the journal of the International Menopause Society

GLP-1 receptor drugs in perimenopause and early menopause: medical uses, heart and metabolism benefits, and what we still need to learnGLP-1 receptor agonists in perimenopause and early postmenopause: clinical role, cardiometabolic benefits and knowledge gaps.

Article

3 weeks ago • Frontiers in pharmacology

Pasteurized Akkermansia muciniphila as a potential treatment affecting multiple functions in the gut-liver system: current evidence, unclear cause-and-effect, and research prioritiesPasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities.

📖 Top 20% JournalArticle

3 weeks ago • Expert review of clinical immunology

GLP-1 receptor agonists may help brain diseases by changing immune cells and reducing brain inflammationThe therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation.

📖 Top 20% JournalArticle

3 weeks ago • European journal of pharmacology

Tirzepatide reduces liver fat and inflammation in MASLD partly by blocking immune cell signalingTirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling.

📖 Top 20% JournalArticle

3 weeks ago • Diabetes, obesity & metabolism

GLP-1 Receptor Agonist Treatment for Blood Sugar Problems Caused by Steroid Use: A Systematic ReviewGLP-1 Receptor Agonist Therapy for Glucocorticoid-Induced Dysglycaemia: A Systematic Review.

Article

3 weeks ago • Endocrine-related cancer

Effects of a GLP-1 drug and diabetes treatments on growth of certain hormone tumorsEffects of a GLP-1 agonist and anti-diabetic therapies on pheochromocytoma/paraganglioma growth.

Article

3 weeks ago • Revista espanola de enfermedades digestivas

Ischemic colitis linked to oral semaglutide with return after restarting the drugIschemic colitis associated with oral semaglutide with recurrence upon rechallenge.

Article

3 weeks ago • The journal of ECT

Managing Electroconvulsive Therapy in Patients Taking GLP-1 Diabetes Drugs: Balancing Safety, Treatment Following, and ConsistencyNavigating Electroconvulsive Therapy in Patients on GLP-1 Receptor Agonists: Balancing Safety, Compliance, and Treatment Consistency: A Case Report.

📖 Top 50% JournalArticle

3 weeks ago • Frontiers in public health

Adults' understanding, opinions, information sources, and use of weight-loss injections in Al-Ahsa, Saudi ArabiaKnowledge, attitudes, information sources, and use of weight-loss injections among adults in Al-Ahsa, Saudi Arabia: a cross-sectional study.

📖 Top 20% JournalArticle

3 weeks ago • Obesity science & practice

Preventing Weight Gain After Stopping Glucagon-Like Peptide-1 Treatment: A Small Randomized TrialPreventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.

📖 Top 30% JournalArticle

← prevpage 14 of 16next →

Latest GLP-1 Therapies Research Papers